Iron: The Secret Ingredient Breaking PARPi Resistance.

Hamed Alborzinia, José Pedro Friedmann Angeli

Journal: Cancer discovery 2024;14(8):1372-1374

PMID: 39091202

Full Text on Silverchair Information Systems View on PubMed

Abstract

PARP inhibitors (PARPi) are used as a first-line treatment option for cancers with BRCA1/2 mutations, yet a significant number of patients show a limited response to these agents. In the present study, Lei and colleagues demonstrate that PARPi promote increased ferroptosis sensitivity and this can be exploited therapeutically to improve the response to PARPi, marking an important therapeutic concept to exploit ferroptosis-based strategies in clinical settings. See related article by Lei et al., p. 1476 (2).

Address: Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany.; Rudolf Virchow Zentrum, Center for Integrative and Translational Bioimaging, Julius-Maximilians-University Würzburg, Würzburg, Germany.

DOI: 10.1158/2159-8290.CD-24-0775

Link outs

Free resources

Medical:

https://medlineplus.gov/iron.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-916

Subscription / membership required

Full Text Sources:

https://aacrjournals.org/cancerdiscovery/article-l...

MeSH Terms: Humans, Poly(ADP-ribose) Polymerase Inhibitors, Drug Resistance, Neoplasm, Ferroptosis, Iron, Neoplasms